Clinical trial
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in…
NCT00450580 · ViiV Healthcare, Industry · Completed
Key facts
| NCT number | NCT00450580 |
|---|---|
| Title | HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults |
| Official title | Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects. |
| Lead sponsor | ViiV Healthcare, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infection, Human Immunodeficiency Virus I, HIV-1 Infection |
| Intervention type | Drug |
| Interventions | fosamprenavir/ritonavir |
| Enrollment | 212 |
| Start date | Mar 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Mar 22, 2007 |
| Last update posted | Jun 7, 2012 |
| Countries | Belgium, France, Germany, Italy, Romania, Russia, Spain, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: